A Study of the SynCardia Temporary Total Artificial Heart Used as End Point Therapy

Overview

About this study

The purpose of this study is to evaluate whether the  Temporary Total   Artificial Heart can support patients with life-threatening irreversible biventricular heart failure who are not eligible for transplantation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria  

  • Primary arm
    • Life-threatening, irreversible biventricular heart failure (Intermacs Patient Profile Classifications 1 - 4)
    • Ineligible for cardiac transplantation (e.g., contraindication to immunosuppression, cancer, elevated panel reactive antibodies [PRAs]) as determined by the implanting center at time of implant screening assessment
    • On optimal medical management and failing to respond or failing DT VAD therapy (continuing to decline)
    • Between 19 and 75 years of age
    • Body Surface Area (BSA) of ≥ 1.7m2
    • Sternum to T10 distance > 10cm OR adequate room in chest as determined by 3-D imaging assessment or by other standard clinical assessments
  • Secondary arm
    • Are NOT eligible to participate in the Primary Arm
    • Have life-threatening, irreversible biventricular heart failure (Intermacs Patient Profile Classifications 1 - 7)
    • Ineligible for cardiac transplantation (as determined by the implanting center at time of implant screening assessment)
    • On optimal medical management and failing to respond or failing DT VAD therapy (continuing to decline)
    • 19 years of age or older
    • Sternum to T10 distance > 10cm OR adequate room in chest as determined by 3-D imaging assessment or by other standard clinical assessments

Exclusion Criteria

  • Primary arm
    • Cardiac transplant-eligible
    • Cannot be adequately anticoagulated on the Temporary total artificial heart
    • Have insufficient space in the chest
    • On ECMO support
    • Have cirrhosis (evidenced by ultrasound, CT scan, or positive biopsy)
    • Acute or chronic renal dysfunction (per Intermacs AE Definitions)
    • Have cardiac cachexia (e.g., pre-albumin <17, fragility, and catabolic/anabolic imbalance)
    • A comorbidity that has a poor prognosis of survival beyond six months
    • Insufficient social support 
    • Have demonstrated non-compliance with medical instructions (as determined by the Principal Investigator)
  •  Secondary arm
    • Less than 19 years old
    • Cardiac transplant-eligible patients
    • Have cirrhosis (evidenced by ultrasound, CT scan, or positive biopsy)
    • Have chronic renal dysfunction (per Intermacs AE Definitions)
    • Insufficient space in the chest
    • Cannot be adequately anticoagulated on the Temporary Total Artificial Heart
    • Insufficient social support
    • Have demonstrated non-compliance with medical instructions (as determined by the Principal Investigator)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lyle Joyce, M.D., Ph.D.

Closed for enrollment

Contact information:

Amy Headlee CCRP

(507) -0406

Headlee.Amy@mayo.edu

More information

Publications

Publications are currently not available